公开(公告)号：KR101472087B1

公开(公告)日：2014-12-16

申请号：KR1020120143628

申请日：2012-12-11

Applicant: 광주과학기술원

Inventor： 박성규 ,  강정아

IPC: C07K14/47 ,  C07K7/00 ,  A61K38/17 ,  A61P37/00

Abstract: 본발명은 T 세포활성을억제하는펩타이드에관한것으로, 서열목록제1서열의아미노산서열을포함하는 PKD1(Phosphoinositide-dependent kinase 1)에서, 제513번째아미노산인트레오닌(Threonine)이인산화모방(phosphomimic) 아미노산또는인산화불능(phosphorylation-disabled) 아미노산으로치환되어있고상기치환된제513번째아미노산을포함하는 8-50개의연속아미노산으로구성된펩타이드이다. 종래의 PDK1 조절자는 PDK1 키나아제의활성을조절하는합성화합물이대부분으로, 이러한합성화합물은 PDK1의기능을광범위하게조절하여부작용을유발할 가능성이있다. 본발명의펩타이드는 PDK1에의한 T 세포및 NF-&kgr;B의활성을특이적으로조절하므로부작용의가능성이낮다.

公开(公告)号：KR102132904B1

公开(公告)日：2020-07-13

申请号：KR1020180098778

申请日：2018-08-23

Applicant: 광주과학기술원 ,  차의과학대학교 산학협력단 ,  서울대학교병원

Inventor： 박성규 ,  강정아 ,  조유리 ,  김윤준

IPC: A61K31/4412 ,  A61K31/522 ,  A61K31/675 ,  A61P31/20 ,  A23L33/10

公开(公告)号：KR1020140075360A

公开(公告)日：2014-06-19

申请号：KR1020120143628

申请日：2012-12-11

Applicant: 광주과학기술원

Inventor： 박성규 ,  강정아

IPC: C07K14/47 ,  C07K7/00 ,  A61K38/17 ,  A61P37/00

Abstract: The present invention relates to peptide inhibiting T cell activity. In phosphoinositide-dependent kinase 1 (PDK1) including a first amino acid sequence of the sequence listing, 513th amino acid, Threonine is substituted with phosphomimic or phosphorylation-disabled amino acid, and the peptide consists of 8 to 50 sequential amino acids including the substituted 513th amino acid. Existing PDK1 regulators are mostly synthetic compounds regulating the activity of PDK1 kinase, and the synthetic compounds have a possibility of causing side effects by widely regulating the PDK1 functions. The peptide in the present invention specifically regulates T cell and NF-κB activities induced by PDK1, thereby being unlikely to cause the side effects.

Abstract translation: 本发明涉及肽抑制性T细胞活性。 在包含序列表的第一个氨基酸序列的磷酸肌醇依赖性激酶1（PDK1）中，第513位氨基酸，苏氨酸被磷酸化或磷酸化残基的氨基酸取代，并且该肽由8至50个连续氨基酸组成，包括经取代 第513位氨基酸。 现有的PDK1调节剂主要是调节PDK1激酶活性的合成化合物，合成化合物可能通过广泛调节PDK1功能而引起副作用。 本发明的肽特异性调节由PDK1诱导的T细胞和NF-κB活性，不可能引起副作用。